Protocol
Testosterone therapy for men with low testosterone and low sex drive
In two randomized trials of men with low testosterone, testosterone gel improved sexual activity and sexual desire against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received.: the Testosterone Trials (790 men aged 65 or older, 1 year) and the TRAVERSE sexual function study (1,161 men aged 45 to 80 with low libido, effect held at 24 months).
At a glance
Some men have low testosterone and a low sex drive. In two trials, testosterone gel gave them more sex and more desire than a dummy gel, and the effect lasted two years. It did not give them more energy. In the largest trial it did not raise heart attacks or strokes. But men on it had more irregular heartbeat, kidney problems, lung clots and broken bones.
- What was measured
- Sexual acts per day, recorded by the men on a daily questionnaire.
- How big
- Sexual activity rose by 0.49 acts per day at 6 months and 0.47 at 12 months more than with placebo.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 37589949.
- Who it applies to
- Men aged 45 or older with low testosterone, symptoms and low sex drive.
- Safety
- More irregular heartbeat, kidney injury, lung clots and fractures in the largest trial.
- Compared with
- A placebo gel.
- Certainty
- Grade B, resting on: Two randomized placebo-controlled trials with self-reported sexual outcomes, plus a large safety trial.
- What would change this grade
- Could rise to A with: Randomized trial of testosterone. Who: Men with low testosterone and low libido. Measured: Sexual activity recorded by a validated objective method. Length: At least 12 months.
- Cost
- No price recorded yet.
- Sources
- 4 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In two randomized trials of men with low testosterone, testosterone gel improved sexual activity and sexual desire against placebo: the Testosterone Trials (790 men aged 65 or older, 1 year) and the TRAVERSE sexual function study (1,161 men aged 45 to 80 with low libido, effect held at 24 months). In TRAVERSE as a whole, testosterone did not raise major heart events, but atrial fibrillation, acute kidney injury, blood clots in the lungs and fractures were more common.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on sexual activity in men with low testosterone and low sex drive. The TRAVERSE sexual function study found more sexual activity with testosterone at 6, 12 and 24 months (Pencina et al., 2023; PMID 37589949), and the Testosterone Trials found the same in men aged 65 or older (Snyder et al., 2016; PMID 26886521).
WHY NOT Asexual activity is recorded by the men themselves on a questionnaire, a self-reported endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. that caps at B. FUNDING: TRAVERSE was funded by AbbVie, a maker of testosterone gel. HARMS: in TRAVERSE, atrial fibrillation, acute kidney injury and pulmonary embolism were more common with testosterone (Lincoff et al., 2023; PMID 37326322), and clinical fractures were more common (HR 1.43; Snyder et al., 2024; PMID 38231621).
WHAT THIS GRADE DOES NOT COVERenergy and vitality, which did not improve; erectile function, which improved in one trial and not the other; men with normal testosterone; and muscle, bone or longevity claims, which these trials do not support.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial, industry-sponsored
Endpoint graded: Sexual activity (daily questionnaire) (self_report)
Last reviewed: November 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
Self-reported outcomes cap the letter at B.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Testosterone among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Testosterone on ClinicalTrials.gov
Dose, form and timing
Testosterone level, hematocrit, heart rhythm symptoms, and fracture risk factors.
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Safety
Cautions documented in human studies. Each caution on this record, sorted by what it rests on.
- Atrial fibrillation, acute kidney injury and pulmonary embolism more common with testosterone in TRAVERSE (PMID 37326322)
- Clinical fractures more common with testosterone in TRAVERSE (3.50% against 2.46%) (PMID 38231621)
None recorded.
None recorded.
- Men with prostate cancer, high hematocrit or untreated sleep apnea were excluded from the trials
Does not apply: human harm data are listed above.
Grade history
How this letter has changedLatest: No. 472 · November 2026 · First graded.
New record in the gap-report batch. In two randomized trials of men with low testosterone, testosterone gel improved sexual activity and sexual desire against placebo: the Testosterone Trials (790 men aged 65 or older, 1 year) and the TRAVERSE sexual function study (1,161 men aged 45 to 80 with low libido, effect held at 24 months). In TRAVERSE as a whole, testosterone did not raise major heart events, but atrial fibrillation, acute kidney injury, blood clots in the lungs and fractures were more common.PMID 37589949 PMID 26886521 PMID 37326322 PMID 38231621
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullFour papers, each linked to its PubMed record.
Pencina et al. (J Clin Endocrinol Metab, 2023; PMID 37589949): TRAVERSE Sexual Function Study, 1,161 men aged 45 to 80 with hypogonadism and low libido, 1.62% testosterone gel against placebo; sexual activity 0.49 (95% CI 0.19 to 0.79) and 0.47 (0.11 to 0.83) more acts per day at 6 and 12 months, maintained at 24 months; desire improved, erectile function did not. Snyder et al. (N Engl J Med, 2016; PMID 26886521): Testosterone Trials, 790 men aged 65 or older with testosterone below 275 ng/dL, testosterone or placebo gel for 1 year; sexual activity, desire and erectile function increased; no benefit for vitality. Lincoff et al. (N Engl J Med, 2023; PMID 37326322): TRAVERSE, 5,246 men; major cardiovascular events HR 0.96 (non-inferior); higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism. Snyder et al. (N Engl J Med, 2024; PMID 38231621): TRAVERSE fracture analysis, clinical fracture 3.50% against 2.46% (HR 1.43, 95% CI 1.04 to 1.97); funded by AbbVie and others.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
testosterone[tiab] AND (sexual[tiab] OR libido[tiab]) AND hypogonad*[tiab] AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Pencina et al., 2024, J Clin Endocrinol Metab (PMID 37589949): PubMed lists funding from AbbVie, Inc; Boston Claude D. Pepper Older Americans Independence Center; US National Institutes of Health (National Institute on Aging).
- Snyder et al., 2016, N Engl J Med (PMID 26886521): PubMed lists funding from National Institutes of Health and others; US National Institutes of Health (National Institute on Aging); US National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases); US National Institutes of Health (National Center for Advancing Translational Sciences); US National Institutes of Health.
- Lincoff et al., 2023, N Engl J Med (PMID 37326322): PubMed lists funding from AbbVie and others.
- Snyder et al., 2024, N Engl J Med (PMID 38231621): PubMed lists funding from AbbVie and others.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →